Primary Cutaneous Peripheral T-Cell Lymphoma Not Otherwise Specified: A Rapidly Progressive Variant of Cutaneous T-Cell Lymphoma. by Aderhold, Kimberly et al.
Tower Health 
Scholar Commons @ Tower Health 
Reading Hospital Internal Medicine Residency Internal Medicine Residency (Faculty and Residents) 
1-1-2015 
Primary Cutaneous Peripheral T-Cell Lymphoma Not Otherwise 
Specified: A Rapidly Progressive Variant of Cutaneous T-Cell 
Lymphoma. 
Kimberly Aderhold 






Reading Hospital, anthony.donato@towerhealth.org 
Follow this and additional works at: https://scholarcommons.towerhealth.org/
gme_int_med_resident_program_read 
 Part of the Internal Medicine Commons 
Recommended Citation 
Aderhold, K., Carpenter, L., Brown, K., & Donato, A. (2015). Primary Cutaneous Peripheral T-Cell Lymphoma 
Not Otherwise Specified: A Rapidly Progressive Variant of Cutaneous T-Cell Lymphoma.. Case Rep Oncol 
Med, 2015 https://doi.org/10.1155/2015/429068 
This Article is brought to you for free and open access by the Internal Medicine Residency (Faculty and Residents) 
at Scholar Commons @ Tower Health. It has been accepted for inclusion in Reading Hospital Internal Medicine 
Residency by an authorized administrator of Scholar Commons @ Tower Health. For more information, please 
contact alexandra.short@towerhealth.org. 
Case Report
Primary Cutaneous Peripheral T-Cell Lymphoma
Not Otherwise Specified: A Rapidly Progressive Variant of
Cutaneous T-Cell Lymphoma
Kimberly Aderhold, Lisa Carpenter, Krysta Brown, and Anthony Donato
Department of Internal Medicine, Reading Health System, West Reading, PA 19608, USA
Correspondence should be addressed to Kimberly Aderhold; kimberly.aderhold@readinghealth.org
Received 14 July 2015; Accepted 19 August 2015
Academic Editor: Junya Kuroda
Copyright © 2015 Kimberly Aderhold et al. This is an open access article distributed under the Creative Commons Attribution
License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly
cited.
Primary Cutaneous Peripheral T-Cell Lymphoma NOS (PTL-NOS) is a rare, progressive, fatal dermatologic disease that presents
with features similar tomany common benign plaque-like skin conditions, making recognition of its distinguishing features critical
for early diagnosis and treatment (Bolognia et al., 2008). A 78-year-old woman presented to ambulatory care with a single 5 cm
nodule on her shoulder that had developed rapidly over 1-2 weeks. Examination was suspicious for malignancy and a biopsy was
performed. Biopsy results demonstrated CD4 positivity, consistent with Mycosis Fungoides with coexpression of CD5, CD47,
and CD7. Within three months her cancer had progressed into diffuse lesions spanning her entire body. As rapid progression is
usually uncharacteristic of Mycosis Fungoides, her diagnosis was amended to PTL-NOS. Cutaneous T-Cell Lymphoma (CTCL)
should be suspected in patients with patches, plaques, erythroderma, or papules that persist or multiply despite conservative
treatment. Singular biopsies are often nondiagnostic, requiring a high degree of suspicion if there is deviation from the anticipated
clinical course. Multiple biopsies are often necessary to make the diagnosis. Physicians caring for patients with rapidly progressive,
nonspecific dermatoses with features described above should keep more uncommon forms of CTCL in mind and refer for early
biopsy.
1. Introduction
Primary Cutaneous Peripheral T-Cell Lymphoma not other-
wise specified (PTL-NOS) is an aggressive and life threaten-
ing dermatologic malignancy that often presents mimicking
other less severe plaque-like skin conditions. Due to the
nonspecific nature of these lesions, CD4-positive CTCL is
often misdiagnosed as either Mycosis Fungoides or Sezary
Syndrome. It is not until the disease progresses that further
investigation into alternative diagnoses is prompted. Biopsy
and immunohistochemical analysis of CTCL are nonspecific
and a discrepancy in the clinical picture may require the
diagnosis to be amended. The 5-year survival rate for PTL-
NOS is less than 20%, which makes timely diagnosis an
important measure to improve outcome [1]. We describe a
patient who presented with a single malignant nodule which
rapidly progressed provoking diagnosis with the rarest form
of CTCL, known as PTL-NOS.
2. Case
A 78-year-old female without significant past medical history
presented to an outpatient surgery center with a two-week
history of a rapidly growing nodule on her right shoulder.
The patient noted that the nodule spontaneously bled as it
became caught on clothing but otherwise was asymptomatic.
She applied Polysporin topically without signs of healing
or regression of the lesion. There were no other lesions of
concern. She admitted to malaise but denied weight loss,
night sweats, fevers, or loss of appetite. Her family history was
negative for any malignancies.
On examination, the patient had a solitary 5 cm ill-
defined, red-violaceous, immobile, irregular nodule on her
right posterior shoulder (Figure 1). The lesion was not
indurated or fluctuant and was nontender to palpation.There
was a small area of excoriation with crusting. Due to the
malignant features of the lesion, a 3mm punch biopsy was
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Figure 1: Initial presentation of the 5 cm nodule found on the right
posterior shoulder.
performed. Laboratory or imaging tests were not performed
at the time of biopsy.
Biopsy revealed a dense pan-dermal infiltrate ofmedium-
to large-sized atypical lymphocytes with irregular nuclei and
perinuclear halos (>25% large cells). The lymphocytes exhib-
ited epidermotropism, blurring the dermal-epidermal junc-
tion and epidermis.The infiltrate formed large groups within
the epidermis and extensively infiltrated the subcutaneous
adipose tissue. Scattered mitotic figures were also identified.
Immunohistochemical staining showed CD4-positive T-cell
population that coexpressed CD5, CD45, and CD7. EBV,
CD30, and CD56 were negative.
These results prompted surgical excision with wide mar-
gins and referral to a hematology/oncology specialist. The
patient was initially diagnosed with Mycosis Fungoides and
was started on Methotrexate. Unfortunately, the Methotrex-
ate proved to be ineffective, and over the next three months
her disease continued to progress with multiple new nodules
and plaques arising over several areas of her body (Figures 2
and 3). Several nodules became ulcerated and productive of
purulent fluid (Figure 4). She additionally developed a lesion
suspicious for metastasis in her spleen that was seen on CT
scan. This lesion was not biopsied per the patient’s request.
After recognizing the aggressive nature of her disease,
her diagnosis was amended to Primary Cutaneous Peripheral
T-Cell Lymphoma, NOS. She was started on combination
Cyclophosphamide, Hydroxydaunomycin (Doxorubicin),
Oncovin (Vincristine), and Prednisone. The disease partially
responded to chemotherapy with regression of lesions on
her lower extremities. Unfortunately the chemotherapy was
poorly tolerated by the patient and, after two cycles of chemo-
therapy, she declined any further treatment. She eventually
succumbed to sepsis due to skin barrier breakdown six
months after diagnosis.
3. Discussion
Cutaneous T-Cell Lymphoma (CTCL) is a form of Non-
Hodgkin Lymphoma that involves neoplasms of T-cells
primarily concentrating within the skin [2]. CTCL can
Figure 2: Diffuse,multifocal red-violaceous nodules on the patient’s
back and neck. Several nodules are ulcerated and crusted and are
exudative.
Figure 3: Multiple scattered irregular nodules on the patient’s legs.
Bandage over excoriated lesion.
vary considerably in clinical presentation, prognosis, and
histological and immunophenotypical description [2]. The
most common forms of CTCL are Mycosis Fungoides and
Sezary Syndrome, which account for about 65% of all CTCL
cases [2]. However, Primary Cutaneous Peripheral T-Cell
Lymphoma not otherwise specified (PTL-NOS) is the rarest
formofCTCL and is a diagnosis of exclusion based on criteria
from the World Health Organization (see below) [1, 2].
Patients with PTL-NOS may present with a solitary
red-violaceous tumor-like nodule on any area of the body;
however, most commonly patients present with scattered
multifocal or diffuse nodules [2]. Many of these tumors
become ulcerated and subsequently infected. Rapid dissem-
ination of the cutaneous tumors and systemic involvement
are unfortunate key features of PTL-NOS contributing to the
five-year survival rate of less than 20% [1, 2].
Due to the rarity of cases, PTL-NOS is not well under-
stood and algorithms for treatment are lacking. PTL-NOS
falls within the rarest CTCL subtype of Primary Cutaneous
Lymphomas (PCLs) and accounts for only about 2% of
PCLs [1, 2]. PTL-NOS may be difficult to diagnose due to
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Figure 4: Ulcerated, necrotic, exudative nodule found on patient’s
R lateral thigh.
the variability of its immunophenotypes; most commonly
tumors are CD4-positive with a variable loss of almost all
T-cell antigens [2]. The CD30 phenotype is usually limited
or absent and rarely CD56 may stain positive [2]. Although
epidermotropism is generally mild or absent, histopatholog-
ically PTL-NOS will display nodular or diffuse infiltrates of
medium- to large-sized pleomorphic or immunoblastic T-
cells [2].
The WHO-EORTC established a set of criteria to help
define PTL-NOS from other, more well-defined rare subtypes
of Primary Cutaneous Lymphomas [1].This criterion is based
on exclusion of three entities that have been recognized
as part of these subtypes: Primary Cutaneous CD4-Positive
Small/Medium T-Cell Lymphoma (CD4+ SMTL), Primary
Cutaneous CD8-Positive Aggressive Epidermotropic T-Cell
Lymphoma (CD8+ AECTCL), and Primary Cutaneous
Gamma/Delta T-Cell Lymphoma (CGD-TCL) [2, 3]. Each
subtype has its own unique immunohistochemical and clin-
ical characteristics [4]. Out of these subtypes, only CD4+
SMTL confers a good prognosis [2, 5]. CD8+ AECTCL
usually presents with rapidly progressing necrotic nodules
and plaques as in PTL-NOS, but with epidermotropic CD8+
atypical lymphocytes [4].
Due to the rarity of PTL-NOS, there are gaps in the
knowledge about evidence-based treatments and survival
[4]. However, it has been shown that age greater than sixty,
Eastern Cooperative Oncology Group (ECOG) performance
status of equal to or greater than two, lactate dehydrogenase
levels at normal values or above, and involvement of the bone
marrow are independent predictors of decreased survival [6].
Due to the rapidly evolving nature of PTL-NOS, treat-
ment usually includes systemic chemotherapy and/or hem-
atopoietic stem cell transplantation [2, 4]. Systemic chemo-
therapy often includes the CHOP multiagent regimen [4].
Since PTL-NOS presents in such an aggressive nature, most
other treatments for CTCL such as interferon-alpha, reti-
noids, PUVA light therapy, and localized radiotherapy are
bypassed [7]. Studies have shown that cytokine treatments
such as interferon-alpha, which are useful in Mycosis Fun-
goides and Sezary Syndrome, not only are ineffective in
PTL-NOS, but may also exacerbate the condition [8]. Even
with systemic chemotherapy and stem cell transplantation,
prognosis is unfortunately still very poor for patients with
PTL-NOS [4].
4. Conclusion
CTCL should be suspected in patients with patches, plaques,
erythroderma, or papules that persist or multiply despite
conservative treatment. Initial biopsies are often nondiag-
nostic. Diagnosis requires a high degree of suspicion and
multiple rebiopsies are often necessary tomake the diagnosis.
Although Mycosis Fungoides is the most common form of
CD4-positive CTCL, it is prudent to consider PTL-NOS as
the initial diagnosis for such a presentation, bearing in mind
the rarity of the disease and nonspecific immunohistochem-
ical analysis. One must have a high index of suspicion for
alternative diagnoses if clinical progression is inconsistent
with usual course of disease.
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